MIRXES-B(02629.HK) plans to collaborate with Jingtai Technology to build an innovative "diagnosis and treatment integration" research and industrialization platform empowered by AI.

Zhixin Finance APP News, MIRXES-B (02629.HK) announced that the company recently signed a memorandum of understanding with Crystal Tai Holdings Limited (Crystal Tai Technology). According to this, both parties agreed to integrate the company's core strengths in genomics technology and its extensive, Asian-centric disease database with Crystal Tai Technology's leading AI+robot drug discovery and research platform, focusing on early detection and intervention of high-incidence cancers in Asia, especially digestive tract cancers. They will jointly establish an innovative "diagnosis and treatment integration" research and industrialization platform empowered by AI, combining diagnosis and treatment, and cooperate to develop early diagnosis and treatment solutions. The memorandum of understanding will take effect from the date of signing and will be valid for two years from the date of signing.